Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13052127 | 0.89 | ADORA2A (0.86) | ADORA2BADORA2A | |
| SCHEMBL3661085 | 0.88 | ADORA2A (0.83) | ADORA2BADORA2A | |
| SCHEMBL24261356 | 0.88 | ADORA2A (0.79) | ADORA2BADORA2A | |
| SCHEMBL3755887 | 0.88 | ADORA2A (0.77) | ADORA2BADORA2A | |
| SCHEMBL3658521 | 0.88 | ADORA2A (1.00) | ADORA2BADORA2A | |
| SCHEMBL3751198 | 0.87 | ADORA2A (0.76) | ADORA2BADORA2A | |
| SCHEMBL20784312 | 0.87 | ADORA2B (0.71) | ADORA2BADORA2A | |
| SCHEMBL3716205 | 0.86 | ADORA2A (1.00) | ADORA2BADORA2A | |
| SCHEMBL3749902 | 0.85 | ADORA2A (0.77) | ADORA2BADORA2A | |
| SCHEMBL3749931 | 0.85 | ADORA2A (1.00) | ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207780-B1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS R&D LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-8354415-B2 | Thienopyrimidine compounds and compositions | VERNALIS (R&D) LTD. (GB) | 2013-01-15 | — | — | US | disclosed |
| US-20100298349-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS (R&D) LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2207780-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | Vernalis (R&D) Ltd. (GB) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009037468-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298349-A1 | THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | ADORA2B, CYP2B6, RRM2B | ADORA2B 1/4885ADORA2A 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.